Cogent Biosciences, Inc. (COGT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$31.21-0.32%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cogent Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	5.98M
EPS	—	-0.562
Annual ending 2026-12-31
Revenue	—	5.98M
EPS	—	-2.216
Annual ending 2027-12-31
Revenue	—	283.69M
EPS	—	-1.091

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Launch bezuclastinib in H2 2026	Cogent Biosciences plans to launch bezuclastinib in the second half of 2026.	Intact	launch delayed beyond 2026-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management has consistently emphasized readiness for launching bezuclastinib in H2 2026 for GIST and Systemic Mastocytosis. Cash and equivalents declined from $866.4M in 2026-Q1 to $792.3M in 2026-Q2, reflecting ongoing investment. R&D expenses remained elevated at $70.8M in 2026-Q2. The trajectory shows active preparation and investment consistent with the launch timeline. Delivery assessment Oct 24, 2026
EPS improvement toward break-even	A supporting condition in Cogent Biosciences, Inc.'s published investment case. The stated target is EPS >= -$0.96 in FY27.	Broken	EPS worse than -$0.96 in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Fund operations into 2028	The company has raised capital to fund operations into 2028.	Intact	cash insufficient to fund operations into 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue growth after bezuclastinib launch	Cogent Biosciences plans to launch bezuclastinib in the second half of 2026.	Improving	revenue falls below $345M in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management has consistently emphasized readiness for launching bezuclastinib in H2 2026 for GIST and Systemic Mastocytosis. Cash and equivalents declined from $866.4M in 2026-Q1 to $792.3M in 2026-Q2, reflecting ongoing investment. R&D expenses remained elevated at $70.8M in 2026-Q2. The trajectory shows active preparation and investment consistent with the launch timeline. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.09

$-0.94 → $-1.09 · observed estimates

FY2027 revenue$0.28B

$0.35B → $0.28B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.94	$348,891,610	9 / 11
2026-07-25	$-0.94	$348,891,610	9 / 11
2026-07-26	$-0.94	$348,891,610	9 / 11
2026-07-27	$-0.94	$348,891,610	9 / 11
2026-07-28	$-0.94	$348,891,610	9 / 11
2026-07-29	$-0.94	$348,891,610	9 / 11
2026-07-30	$-0.77	$348,895,417	8 / 9
2026-07-31	$-0.94	$348,891,610	9 / 11
2026-08-01	$-0.77	$348,895,417	8 / 9
2026-08-02	$-0.94	$348,891,610	9 / 11
2026-08-03	$-0.77	$348,895,417	8 / 9
2026-08-04	$-0.94	$348,891,610	9 / 11
2026-08-05	$-0.77	$348,895,417	8 / 9
2026-08-06	$-0.94	$348,891,610	9 / 11
2026-08-07	$-0.77	$348,895,417	8 / 9
2026-08-08	$-0.94	$348,891,610	9 / 11
2026-08-09	$-0.94	$348,891,610	9 / 11
2026-08-10	$-0.77	$348,895,417	8 / 9
2026-08-11	$-0.77	$348,895,417	8 / 9
2026-08-12	$-0.91	$393,655,520	9 / 11
2026-08-13	$-0.77	$348,895,417	8 / 9
2026-08-14	$-0.77	$348,895,417	8 / 9
2026-08-15	$-0.77	$348,895,417	8 / 9
2026-08-16	$-0.77	$348,895,417	8 / 9
2026-08-17	$-0.77	$348,895,417	8 / 9
2026-08-18	$-0.77	$348,895,417	8 / 9
2026-08-19	$-0.77	$348,895,417	8 / 9
2026-08-20	$-0.94	$315,773,152	8 / 8
2026-08-21	$-0.97	$310,294,736	7 / 9
2026-08-22	$-0.97	$310,294,736	8 / 9
2026-08-23	$-0.97	$310,294,736	8 / 9
2026-08-24	$-0.97	$310,294,736	8 / 9
2026-08-25	$-0.97	$310,294,736	8 / 9
2026-08-26	$-0.97	$310,294,736	8 / 9
2026-08-27	$-0.97	$310,294,736	8 / 9
2026-08-28	$-0.97	$310,294,736	8 / 9
2026-08-29	$-1.03	$292,762,721	8 / 9
2026-08-30	$-1.03	$292,762,721	8 / 9
2026-08-31	$-1.03	$292,762,721	8 / 9
2026-09-01	$-1.03	$292,762,721	8 / 9
2026-09-02	$-1.03	$292,762,721	8 / 9
2026-09-03	$-1.03	$292,762,721	8 / 9
2026-09-04	$-1.03	$292,762,721	8 / 9
2026-09-05	$-1.03	$292,762,721	8 / 9
2026-09-06	$-1.03	$292,762,721	8 / 9
2026-09-07	$-1.03	$292,762,721	8 / 9
2026-09-08	$-1.03	$292,762,721	8 / 9
2026-09-09	$-1.03	$292,762,721	8 / 9
2026-09-10	$-1.02	$294,813,397	8 / 9
2026-09-11	$-1.02	$294,813,397	8 / 9
2026-09-12	$-1.02	$294,813,397	8 / 9
2026-09-13	$-1.02	$294,813,397	8 / 9
2026-09-14	$-1.02	$294,813,397	8 / 9
2026-09-15	$-1.02	$294,813,397	8 / 9
2026-09-16	$-1.03	$292,940,669	8 / 9
2026-09-17	$-1.03	$292,804,942	8 / 9
2026-09-18	$-1.03	$292,804,942	8 / 9
2026-09-19	$-1.03	$292,804,942	8 / 9
2026-09-20	$-1.03	$292,804,942	8 / 9
2026-09-21	$-1.03	$292,804,942	8 / 9
2026-09-22	$-1.03	$292,804,942	8 / 9
2026-09-23	$-1.03	$292,804,942	8 / 9
2026-09-24	$-1.03	$292,804,942	8 / 9
2026-09-25	$-1.03	$292,804,942	8 / 9
2026-09-26	$-1.03	$292,804,942	8 / 9
2026-09-27	$-1.03	$292,804,942	8 / 9
2026-09-28	$-1.03	$292,804,942	8 / 9
2026-09-29	$-1.03	$292,804,942	8 / 9
2026-09-30	$-1.03	$292,804,942	8 / 9
2026-10-01	$-1.03	$292,804,942	8 / 9
2026-10-02	$-1.03	$292,804,942	8 / 9
2026-10-03	$-1.03	$292,804,942	8 / 9
2026-10-04	$-1.03	$292,804,942	8 / 9
2026-10-05	$-1.03	$292,804,942	8 / 9
2026-10-06	$-1.03	$292,804,942	8 / 9
2026-10-07	$-1.03	$292,804,942	8 / 9
2026-10-08	$-1.03	$292,804,942	8 / 9
2026-10-09	$-1.03	$292,804,942	8 / 9
2026-10-10	$-1.03	$292,804,942	8 / 9
2026-10-11	$-1.03	$292,804,942	8 / 9
2026-10-12	$-1.03	$292,804,942	8 / 9
2026-10-13	$-1.03	$292,804,942	8 / 9
2026-10-14	$-1.03	$292,804,942	8 / 9
2026-10-15	$-1.08	$283,687,541	8 / 9
2026-10-16	$-1.08	$283,687,541	8 / 9
2026-10-17	$-1.08	$283,687,541	8 / 9
2026-10-18	$-1.08	$283,687,541	8 / 9
2026-10-19	$-1.08	$283,687,541	8 / 9
2026-10-20	$-1.08	$283,687,541	8 / 9
2026-10-21	$-1.08	$283,687,541	8 / 9
2026-10-22	$-1.09	$283,687,541	8 / 9
2026-10-23	$-1.09	$283,687,541	8 / 9
2026-10-24	$-1.09	$283,687,541	8 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	11	2
2026-06-01	11	2
2026-07-01	11	2
2026-08-01	11	2
2026-09-01	11	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Launch bezuclastinib in H2 2026Direct metric needs a verified mapping
EPS improvement toward break-evenPublished status: Broken
Fund operations into 2028Direct metric needs a verified mapping
Revenue growth after bezuclastinib launchDirect metric needs a verified mapping

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-34.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cogent Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

COGT is a loss-making, clinical-stage biotechnology company with a launch-driven, speculative growth profile. Its multi-year view is watchful: management is investing in a planned bezuclastinib launch and pipeline progress, while recent financial performance remains weak.

What's priced into Cogent Biosciences, Inc.

The evidence provides no valuation level or specific market expectations, so it is not possible to say whether COGT is cheap, fair, or expensive versus peers. The priced-in evidence shows low fragility, but that does not establish that expectations are modest.

What the fundamentals likely do

Near term, results may remain weak as research and development spending stays elevated and cash declines during launch preparation. Management has repeatedly emphasized a second-half 2026 launch and funding operations into late 2028; cash plus stated access to ATM proceeds is intended to support that plan. A guidance cut is a key near-term risk, and the recent earnings beat does not remove the broader execution risk.

What Cogent Biosciences, Inc. hinges on

The multi-year thesis hinges on launching bezuclastinib for GIST and Systemic Mastocytosis on the stated timeline, while maintaining enough funding for operations and pipeline work. Near-term conditions also matter: weaker jobs data could increase recession concerns, while continued strong results from healthcare bellwethers could support sector momentum. Progress on planned IND submissions and dose escalation would provide evidence that the broader pipeline is advancing.